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Chronic inﬂammation of the hair follicle (HF) is considered a contributing factor in the pathogenesis of androgenetic alopecia
(AGA). Previously, we clinically tested liposterolic extract of Serenoa repens (LSESr) and its glycoside, β-sitosterol, in subjects with
AGA and showeda highlypositive response to treatment. In this study, we soughtto determine whether blockade ofinﬂammation
using a composition containing LSESr as well as two anti-inﬂammatory agents (carnitine and thioctic acid) could alter the
expression of molecular markers of inﬂammation in a well-established in vitro system. Using a well-validated assay representative
ofHFkeratinocytes,speciﬁcally, stimulationofcultured humankeratinocytecellsin vitro, we measuredchangesingene expression
of a spectrum of well-known inﬂammatorymarkers. Lipopolysaccharide (LPS) provided an inﬂammatorystimulus.In particular,
we found that the composition eﬀectively suppressed LPS-activated gene expression of chemokines, including CCL17, CXCL6 and
LTB(4) associatedwith pathwaysinvolvedininﬂammationandapoptosis.Ourdatasupport the hypothesisthatthe test compound
exhibits anti-inﬂammatory characteristics in a well-established in vitro assay representing HF keratinocyte gene expression. These
ﬁndings suggest that 5-alpha reductase inhibitors combined with blockade of inﬂammatory processes could represent a novel
two-pronged approach in the treatment of AGA with improved eﬃcacy over current modalities.
1.Introduction
The pathogeneses of benign prostatic hyperplasia (BPH)
and androgenetic alopecia (AGA) are mediated in part
by the transcriptional pathways downstream of the steroid
hormone androgen receptor (AR). The predominant ligand
in these tissues is dihydrotestosterone (DHT), which is
formed by theconversionofthe inactive formoftestosterone
(T)andiscatalyzedbytheenzyme 5-alphareductase (5-AR).
Anti-androgens and inhibitors of 5-AR have proven
eﬀective in the treatment of BPH as well as AGA, attesting to
their common disease mechanisms. Boththe pharmaceutical
compound, ﬁnasteride (Proscar or Propecia) and the lipo-
sterolicextract ofSerenoa repens(LSESr)haveshown eﬃcacy
in the treatment of BPH and AGA. Notably, in a direct
comparison of LSESragainst ﬁnasteride, it has been reported
that LSESr exhibited a 3-fold greater inhibition of 5-AR in in
vitro assays [1].
Finasteride (at a dose of 5mg, as in Proscar) is used as
the treatment of choice for BPH, particularly in the USA.
A number of well-controlled studies point to its eﬃcacy in
ameliorating the signs and symptoms of BPH [2]. In large,
double-blind, placebo-controlled clinical studies recruiting
over 1600 patients, it was shown that the administration of
ﬁnasteride reduced the size ofthe prostate by a mean of22%,
following 6 months of therapy [3]. Likewise, multiple well-
controlled clinical trials reinforce the utility of LSESr in the
setting of BPH, predominantly in Europe [4]. Investigators
have found that LSESr is well tolerated and has greater
eﬃcacy than placebo and similar eﬃcacy to ﬁnasteride in
improving symptoms in men with BPH [5].
During the course of a clinical trial of Proscar for BPH,
it was noted serendipitously that there was a cessation of
hair loss in study subjects receiving drug [6]. Therefore,
ﬁnasteride (at a dose of 1mg; as in Propecia) was subse-
quently investigated in clinical trials for the treatment of
m e nw i t hA G A .I na ﬀected individuals, long-term treatment
with ﬁnasteride 1 mg/day over 5 years was well-tolerated,
led to visible improvements in scalp hair growth and slowed
the further progression of hair loss that occurred without2 Evidence-Based Complementary and Alternative Medicine
treatment [7] .L S E S ri sw e l lk n o w nf o ri t sr o l ei nB P Ha sa5 -
AR inhibitor, leading us to postulate a similar eﬀect in AGA.
Previously,we tested LSESranditsglycoside,β-sitosterol,
in subjects with AGA and showed a highly positive response
to treatment. The blinded investigative staﬀ assessment
reported that 60% of study subjects dosed with the active
study formulation were rated as improved at the conclusion
of the trial and established the eﬀectiveness of naturally
occurring 5-AR inhibitors against AGA for the ﬁrst time [8].
Notwithstanding, the common mechanism of androgens
in their pathogenesis, several lines of emerging evidence
suggest that both BPH and AGA are also associated with
signiﬁcant dysregulation in the expression of inﬂammatory
cytokines [9]. For example, gene expression proﬁling of
prostate tissue from BPH patients revealed molecular signa-
tures containing genes associated with inﬂammation [10].
Likewise, chronic inﬂammation of the hair follicle (HF) is
also considered a contributing factor in AGA [11]. Another
recent study reported a relationship between moderate to
extensive alopeciaand chroniclow-grade inﬂammation [12].
Histologically, it has been shown that in scalp biopsies
from AGA patients, sustained follicular inﬂammation with
connectivetissueremodelingeventuallyresultsinpermanent
hair loss and, thus, is described as a possible cofactor in the
complex etiology of the disorder [11].
On the basis of such ﬁndings, the utility of treating
BPH-aﬀected patients with anti-inﬂammatory agents in
combination with 5-AR inhibitors is currently under inves-
tigation. In one study, combination therapy with alpha(1)-
adrenergic receptor antagonists [alpha(1)-ARAs] and the 5-
AR inhibitor ﬁnasteride was signiﬁcantly more eﬀective than
either component alone in reducing BPH-related symptoms
(P = .006 versus doxazosin monotherapy; P<. 001 versus
ﬁnasteride monotherapy) and lowering the rate of overall
clinical progression (P<. 001 versus either monotherapy
alone) [13]. The greatest eﬃcacy was observed in patients
with a markedly enlarged prostate, more severe symptoms
and higher PSA levels. These data suggest that the treatment
of BPH is enhanced by the use of anti-inﬂammatory agents
in combination with 5-AR blockade [14]. Taken together,
these lines of evidence led us to postulate that inﬂammation
is a rational therapeutic target in pattern hair loss (AGA).
In this study, we sought to determine whether blockade
of inﬂammation using a composition containing LSESr,
carnitine and thioctic acid (TA) could alter the expression
of molecular markers of inﬂammation in a well-established
in vitro system. We found that our compound eﬀectively
repressed LPS-activated expression of a number of genes
involved in skin inﬂammation and apoptosis. Our ﬁndings
suggest that 5-AR inhibitors combined with blockade of
inﬂammatory processescouldrepresentanoveltwo-pronged
approach in the treatment of AGA with improved eﬃcacy
over current modalities.
2.Methods
2.1. Cell Culture and Challenge. Human keratinocyte cells
(HaCaT) were grown in low glucose DMEM supplemented
with 10% FBS, 2mM l-glutamine, 1mM sodium pyruvate
solution, 0.1mM NEAA, 100Uml−1 penicillin, 100μgml −1
streptomycin at 37◦Ca n d5 %C O 2. They were subcultured
on Day 2 and grown to 80% conﬂuency on six-well plates.
TheHaCaTcellsweretreatedwitheither100ngor200ng
of LPS (Sigma, St Louis, MO, USA) for 2h. The media was
thenreplacedwithfresh LPS atthesame concentrationalong
with the LSESr, TA and carnitine test substance, hereafter
designated as TS-050508A (1:1000). Each condition was
carried out in triplicate. The cells were harvested in 1ml
trizol after 22h. Control wells were treated with 100ng or
200ng for 24h and harvested in 1ml trizol. Alternately, the
HaCat cells were treated with TS-050508A (1:1000) for 2h.
The media was then replaced with either 100ng or 200ng of
LPS along with fresh TS-050508A (1:1000). Each condition
was carried out in triplicate. The cells were harvested in 1ml
trizol after 22h. Control wells were treated with TS-050508A
(1:1000) for 24h and harvested in 1ml trizol. Cell viability
was determined by trypan blue staining.
2.2. Trypan Blue Staining. The HaCaT cells were treated
with 0.5 ml 0.05% trypsin–EDTA and placed at 37◦Ci n
5%CO2 for 12min. The cells were neutralized with 0.5 ml
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) 10% Fetal
Bovine Serum (FBS). 30 μlo ft r y p a nb l u ew a sm i x e dw i t h
30μl of cell suspension. Approximately 10μl was loaded into
a haemocytometer and the cells were counted. Counts were
takenat 3, 6, 12and 24h for the NoLPS, 100, 200 and 400ng
LPS conditions, respectively. Under our culture conditions
and over this concentration range of LPS, the eﬀects of LPS
on cell viability, as measured by trypan blue, were variable
but there was no consistent decrease in viability as LPS
concentration increased. Therefore, we used LPS at the lower
end of this concentration range to ensure cell viability. Our
ﬁndings are consistent with those observed by others [15].
2.3. Nucleic Acids Preparation and PCR-Based Expression
Array. Total RNA was isolated from all samples using
standard protocols and further cleaned using RNeasy mini
columns according to the manufacturer’s recommendations
(Qiagen, Gaithersburg, MD, USA). The RNA was deemed
of good quality for the 260/280, 260/230 and the 28s/18s
r i b o s o m a lr a t i o sw e r ec l o s et o2 .T h eR N A( 5 0 0n g )w a st h e n
reverse transcribed to cDNAusing the protocolsas suggested
in the RT2 First strand kit (SA Biosciences, Frederick, MD,
USA). The cDNA was then used to prepare a master mix
as per the RT2 qPCR kit protocol (SA Biosciences). A 10μl
aliquot of this mix was loaded on to the wells in a custom
384-well plate (designed to include most of the genes in
the inﬂammation and cytokineresponse pathway). The cycle
time (Ct) values from these reactions were analyzed using the
PCRarray data analysis template to calculate the ΔΔCt and
the fold change [fold change = 2(−ΔΔCt)].
2.4. RT–PCR Validation of Results. Equal amount of RNA
(1μg) was taken for all samples and reverse transcription
was performed using RT2 First Strand kit (Cat# C-03) from
SA Biosciences. The total volume of the reaction was 20μl,
and the ﬁnal RT product was diluted to a volume of 100Evidence-Based Complementary and Alternative Medicine 3
μl. Individual PCR assays were performed with the oﬀ-the-
shelf pre-validated primer pairs from SA Biosciences on the
BioRadiCycleriQusing RT2 SYBRGreen/ROXqPCRMaster
Mix (Cat#PA-011, SABiosciences).PCR assays foreach gene
target were performed in triplicates for each sample. Each
PCR reaction contained cDNA synthesized from 10 ng total
RNA. Relative changes in gene expression were calculated
using theΔΔCt (threshold cycle)method.Foldchange values
are calculated using the formula 2−ΔΔCt. There were three
biological replicates in each treatment group. Comparisons
between groups were made using unpaired Student’s t-tests
with the level of signiﬁcance set at P<. 05.
3.Results
3.1. Test Compound Suppressed LPS-activated Gene Expres-
sion. In this study, we used a well-validated in vitro assay
representative of HF keratinocytes, speciﬁcally, stimulation
of cultured HaCaT cells. We measured changes in gene
expression of a spectrum of well-known inﬂammatory
markers, using lipopolysaccharide (LPS) as an inﬂam-
matory stimulus. Using untreated cells as a baseline for
gene expression, we tested our compound under seven
conditions: (i) 100ng LPS alone (low dose); (ii) 200ng
LPS alone (high dose); (iii) compound alone (1:1000);
(iv) compound followed by low-dose LPS; (v) compound
followed by high-dose LPS; (vi) low-dose LPS followed
by the compound and lastly (vii) high-dose LPS followed
by the compound. Overall, we found that treating HaCaT
cell cultures with our compound resulted in reduced LPS-
mediated inﬂammatory gene expression without inducing a
negative eﬀect on cell viability. In particular, we found that
the composition eﬀectively suppressed LPS-activated gene
expression of chemokines associated with pathways involved
in inﬂammation and apoptosis.
3.2. Global Expression Analysis Reveals Inhibition of Inﬂam-
matory Pathways. The RT2 Proﬁler PCR Array from Super-
Array was used to interrogate the eﬀect of the novel
composition on inﬂammation. This array contains 384 well-
validated genes known to be involved in stromal, endothelial
and epithelial inﬂammatory pathways. The classes of genes
representedonthearray includedtheCCligand chemokines,
toll-like receptor genes and their ligands, epithelial cell
adhesion molecules, and members of the CXC chemokine
family and leukotriene lipid mediators derived from the 5-
lipoxygenase pathway of arachidonic acid metabolism.
When measured against theuntreated cells, we noted sta-
tistically signiﬁcant (P ≤ .05) fold changes in the following
genes: CCL3, CCL8, CCL17, CCL24, CCR7, CXCL2, CXCL6,
IL18RAP, IL1A, IL1B, IL1F10 LTB(4) and TLR4,( Table 1).
Below we will focus on three genes, CCL17, CXCL6 and
LTB(4) (Figure 1).
3.3. Chemokine Ligand CCL17. In this study, our com-
pound showed modest but statistically signiﬁcant anti-
inﬂammatory activity against CCL17. The HaCaT cells
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Figure 1: Noteworthy foldchangeoccurring inCCL17, CXCL6 and
LTB(4).
change as compared to untreated controls. Dosing the cells
with 200ng LPS resulted in a down-regulation of CCL17
by a factor of −1.43-fold. The cells treated with the test
compound alone down-regulated expression of CCL17 by
af a c t o ro f−2.17 from baseline, whereas cells treated with
compound followed by low-dose LPS resulted in a down-
regulation of −1.71-fold. Overall, the results showed that
our compound down-regulated the inﬂammatory marker
CCL17. The test composition also blocked the up-regulation
of message, both prior to and subsequent to LPS-mediated
challenge.
3.4. CXC Chemokine Ligand, CXCL6. We show statistically
signiﬁcant anti-inﬂammatory activity in an LPS-mediated
model of skin inﬂammation via the marker CXCL6. The
low-dose LPS-only (100ng) stimulated cells resulted in
CXCL6 being up-regulated by 1.57-fold. When measured
against baseline, the test compound alone down-regulated
expression of CXCL6 by a factor of −3.09. After incubating
the cells with the test compound followed by exposure
to low-dose LPS, CXCL6 expression showed a −3.28-fold
change as measured against baseline. These results show
a blockade of CXCL6 inﬂammatory message in the LPS-
stimulated HaCaT cells by the test compound.
3.5. Leukotriene B(4). In this study, our test compound
showed a noteworthy eﬀect in the leukotriene [LTB(4)]
marker. The HaCaT cells treated with 100ng LPS inﬂam-
matory agonist displayed an up-regulated fold change for4 Evidence-Based Complementary and Alternative Medicine
Table 1: Gene expression proﬁle of inﬂammatory markers expressing statistically signiﬁcant fold change.
Symbol Well
CCL17 A08 −2.17 1.76 −1.63 −1.71 −1.43 −1.25 −1.49
CCL24 B02 −2.74 −4.12 −1.70 −1.65 −3.95 −5.21 −3.27
CCL3 B03 2.04 1.55 −1.05 2.84 1.77 −1.47
CCL8 B07 −1.01 2.47 1.55 2.01 1.38
CCR7 B12 −2.29 −1.46 −1.96 −1.27 −1.43 −1.67
CXCL2 C08 −2.18 −1.35 −2.22 −3.34
3.31 −
−1.41 −1.27 −2.34
CXCL6 C11 −3.09 1.57 −2.78 −3.28 1.45 −2.30 −4.92
IL18RAP D10 −2.37 −1.01 −1.13
IL1A D11 2.53 −1.73 −1.06 −1.62 2.77
IL1B D12 2.12 −1.21 −1.27 2.39 1.81
IL1F10 E01 3.67 −2.33 −5.36 −4.73 −3.70 −3.95 −5.09
LTB(4) F06 −2.64 1.33 −3.54 −4.59 1.23 −2.44 −4.37
TLR4 G06 2.97 −1.70 2.31 −1.32 3.36
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Dark gray shadings indicates only test sample shows weak ampliﬁcation. Bold text indicates stasticallysigniﬁcant fold changes.
LTB(4) of 1.33 when measured against baseline. Gene
expression of LTB(4) showed a down-regulation of −2.64-
fold in the cells treated with the test compound alone. A
100ng LPS incubated cells followed by the test compound
showed marked change in LTB(4) expression demonstrating
a −4.59-fold change as measured against baseline. These
results show that our compound blockedthe LPS-stimulated
up-regulation of the inﬂammatory marker LTB(4).
In summary, we found that our test compound atten-
uated expression for markers of inﬂammation, and specif-
ically for CCL17, CXCL6 and LTB(4). Our data support
the hypothesis that the test compound exhibits anti-
inﬂammatory characteristics in a well-established in vitro
assay representing HF keratinocyte gene expression.
4.Discussion
Inthisstudy,we sought todemonstratethata testcompound
containing LSESr, carnitine and TA represses LPS-activated
expression of inﬂammatory genes using a well-validated in
vitroassayrepresentativeofHFkeratinocytes,speciﬁcally,the
LPS-stimulated HaCaT cells [16, 17]. We assayed for changes
in gene expression across a spectrum of well-characterized
inﬂammatory markers and found that our test compound
demonstrates anti-inﬂammatory properties in vitro.P l a n t
extracts or mixtures comprise a repertoire of chemical
entities that have pleiotropic eﬀects on cellular physiology.
As such, they have great potential in the multi-target
approach to diseases [18, 19]. Microarray analysis of gene
expression following exposure of cells to plant extracts can
be useful for elucidating the molecular networks impacted
by herbal extracts and mixtures [20]. In particular, plant-
based therapies have proven eﬃcacious in the treatment of
inﬂammatory skin disorders, such as atopic dermatitis [21].
Here, we found that treating HaCaT cell cultures with
our compound resulted in a statistically signiﬁcant (P<
.05) reduction of LPS-mediated inﬂammatory gene expres-
sion without inducing a negative eﬀect on cell viabil-
ity. Speciﬁcally, we noted that the composition eﬀectively
suppressed LPS-activated gene expression of chemokines
CCL17, CXCL6 and LTB(4). The over-expression of each of
these markers has previously been observed in the setting
of inﬂammation and apoptosis. We focused here on short
term and immediate changes in gene expression, using
array hybridization, followed by qPCR. The gene expression
fold changes we observed were statistically signiﬁcant. Our
approach is supported in the literature by many other
examplesusingthesamestrategy,instudyingacuteresponses
to stimuli such as LPS, in addition to UV irradiation and
wounding in the HaCaT cells and keratinocytes [22–25].
Our rationale for selecting CXCL6, CCL17 and LTB(4)
for further study relates to their role in inﬂammatory
disorders of the skin, mucosae and epithelia. CXCL6 is a
CXC chemokine expressed by macrophages, epithelial and
mesenchymal cells during inﬂammation. Recently, it was
shown that the transcriptome of the aging prostate stroma
is characterized by the up-regulation of several genes that
encode secreted inﬂammatory mediators, including CXCL6
[26]. Similarly, in the skin, CCL17 (a CC chemokine ligand)















Figure 2: Many organ systems are aﬀected by pro-inﬂammatory
processes.
CCL17 is also over-expressed in stromal, endothelial and
epithelial tissues in autoimmune disorders including the
inﬂammatory bowel diseases, Crohn’s disease and ulcerative
colitis (UC) [28]. Finally, LTB(4) is a lipid inﬂammatory
mediator derived from membrane phospholipids by the
sequential actions of cytosolic phospholipase A2 (PLA2), 5-
lipoxygenase (5-LO) and leukotriene A(4) [LTA(4)] hydro-
lase. LTB(4), best known as a neutrophil chemoattractant, is
now recognized to exert other important eﬀects contribut-
ing to inﬂammatory and immune responses. Reinforcing
the connection between androgen-mediated disorders and
inﬂammatory processes, LTB(4)expression hasbeendemon-
strated in acne vulgaris [29].
While LPS caused upregulation of CXCL6 and LTB(4)
at both doses as expected, we observed a modest downreg-
ulation of CCL17 at the higher dose of LPS. Likewise, in a
recent study using the LPS challenge cell culture model, the
authors noted that their responses might have also diﬀered
from predicted expectation based on the presence orabsence
of speciﬁc cell-surface receptors in 2D culture versus the
3D environment [30]. Thus, the observation that high-dose
LPS itself partially lowers CCL17 expression does not change
our interpretation, since the treatment represses expression
beyond the level of high-dose LPS. The overall result of
our experiment is that LPS challenge (at low dose) induces
the expected increase in CCL17, and the treatment group
demonstrates potent downregulation of CCL17.
A large body of evidence supports the involvement
of pro-inﬂammatory processes in the development and
progression of numerous disorders, including inﬂammatory
bowel disease, ischemic heart disease and asthma (Figure 2)
[18]. Chronic inﬂammation is recognized at the molecular
and cellular levels as the ﬁnal common pathway of many sys-
temicand degenerativediseases, includingthoseaﬀectingthe
skin [31]. It has also been observed that inﬂammation, even
that induced by emotional stress, plays a role in hair loss,
and recent studies point to inﬂammation as a contributing
factor to AGA [32]. In a murine model, the authors demon-
strated that psychoemotional stress indeed alters actual HF
cycling in vivo, that is, prematurely terminates the normal
duration of active hair growth (anagen) [33]. Furthermore,
inﬂammatory events deleterious to the HF are present in the
HF environment of stressed mice (perifollicular macrophage
cluster, excessive mast cell activation). It has also been shown
experimentally that high-dose pro-inﬂammatory cytokines
induce apoptosis of HF keratinocytes in vivo [34].
Histologically, sustained microscopic follicular inﬂam-
mation with connective tissue remodeling is a noted cofactor
in the complex etiology of AGA [35]. Disruption of HF
homeostasis, via injury, insult or inﬂammation results in
a shift from proliferation to apoptosis. Cumulatively, these
ﬁndings underline the susceptibility HFs display when
subjected to inﬂammatory insult.
In order to clarify the rationale leading to this study,
l-carnitine, TA and LSESr operate through distinct, but
potentially interrelated, biochemical and molecular mech-
anisms, with each representing an important component
in the design of the test formula. Carnitine, a potent anti-
inﬂammatory agent, biosynthesized from the amino acids
lysine and methionine is required for the transport of fatty
acids from the cytosol into the mitochondria during the
breakdown of lipids for the generation of metabolic energy
[36]. Carnitine exists in two stereoisomers: its biologically
active form is l-carnitine, while its enantiomer, d-carnitine,
is biologically inactive [37].
Accumulating evidence suggests that l-carnitine may
play a signiﬁcant role in prevention and treatment ofnumer-
o u sd i s e a s e sa sw e l la sp r o t e c t i o nf r o ma c c e l e r a t e da g i n g
that result from oxygen free-radical damage, inﬂammation
and glycation (non-enzymatic glycosylation). Documented
beneﬁts from l-carnitine include clinical improvement in
patients diagnosed with diabetes, cardiovascular disease,
hypertension, congestive heart failure, age-related deterio-
ration of brain function and vision and immune function
[38]. One line of research suggests that carnitine may possess
the ability to promote hair growth in vitro by increasing
energy supply to the rapidly prolife rating and the energy-
consuming anagen hair matrix [39].
The naturally occurring antioxidant TA was ﬁrst
described as an essential cofactor for the conversion of
pyruvate to acetyl-CoA, a critical step in respiration [40]. TA
isnowrecognized asacompoundwith manybiologicalfunc-
tions, such as the modulation of pathogenic inﬂammatory
events, including those in the skin [41].
In addition to the two constituents described above, the
test compoundalsocontainstheLSESrderivedfrom thefruit
ofsaw palmetto.LSESrishighlyenriched withfattyacidsand
phytosterols and has been used historically to treat urinary
tract symptoms, including BPH [42]. LSESr has been shown
to block both isoforms of 5-alpha reductase (types I and
II) with the added beneﬁt that, in contrast to ﬁnasteride,
LSESrdoesnot interfere with PSA(prostate-speciﬁc antigen)
levels [43]. As previously noted, we were the ﬁrst to clinically
demonstrate the utility of LSESr against AGA [8].6 Evidence-Based Complementary and Alternative Medicine
While the genetic architecture of AGA has not yet been
determined, it is clearly a polygenic disorder in which mul-
tiple genes, hormonal pathways and environmental factors
contribute to phenotype. To date, DHT modulation via
5-AR blockade remains the only druggable target shown
to ameliorate the progression of AGA [44]. An important
feature of our hypothesis hinges on the enhanced eﬃcacy of
combining anti-inﬂammatory agents with 5-AR inhibitors.
A paradigm for enhanced performance via concomitant
therapy already exists in the treatment of skin disease. For
example, studies show that the addition of a topical corti-
costeroid to imidazole therapy increases the bioavailability
and prolongs the activity of the antimycotic, while rapidly
reducing inﬂammatory symptoms [45].
In several studies, a synergy between TA and vitamin E
has been described, and potent antioxidant eﬀects can be
obtained when both antioxidants are simultaneously used.
Speciﬁcally, recent ﬁndings showed that the combination of
TA plus vitamin E eﬀectively reduces oxidative damage in
brain and cardiac ischemia as well as in other pathological
events associated with tissue inﬂammation and secondary to
the formation of reactive oxygen species (ROS) [46]. In in
vitro and animal studies, l-carnitine, particularly when used
in combination with TA, has been shown to reverse age-
related changes in numerous tissues, systems and pathways
[47].
Since the clinical success rate for treatment of AGA with
androgen blockade is limited, there is enormous unmet
medical need for patients who are refractory to current
therapy. Recognizing that inﬂammation contributes to a
wide range of diseases, including those aﬀecting the skin and
hair, it is our hypothesis that the blockade of inﬂammation
represents a new and potentially viable therapeutic avenue.
We suggest that our data may oﬀer new insight into the
potentialfor combininganti-inﬂammatory compounds with
5-AR inhibitors for the treatment of AGA.
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